SCYNEXIS Inc (LTS:0L49)
$ 1.31 -0.055 (-4.03%) Market Cap: 49.97 Mil Enterprise Value: -7.52 Mil PE Ratio: 0 PB Ratio: 0.83 GF Score: 43/100

SCYNEXIS Inc Corporate Commercial Launch Update Corporate Call Transcript

Jun 29, 2021 / 04:00PM GMT
Release Date Price: $7.18
Operator

Good afternoon, and welcome to the SCYNEXIS Conference Call. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the SCYNEXIS' website following the conclusion of the event. I would now like to turn the call over to Irina Koffler of LifeSci Advisors. You may being.

Irina Koffler
LifeSci Advisors, LLC - MD

Good afternoon, and thank you for joining us as we provide a corporate update on the pending BREXAFEMME launch for the treatment of VVC. Joining me today from SCYNEXIS are Dr. Marco Taglietti, President and Chief Executive Officer; Dr. Michael Krychman, Health Science, Clinical Professor at the University of California Irvine, Division of Gynecological Oncology; Christine Coyne, Chief Commercial Officer; and Eric Francois, Chief Financial Officer.

During this call, please note, we will be making forward-looking statements. These statements are subject to factors, risks and uncertainties, including those that are detailed in today's presentation and our Form 10-K for the year ended December 31,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot